Novo Nordisk Korea said it signed a memorandum of understanding (MOU) with Seoul National University Bundang Hospital (SNUBH) to enhance global clinical trial participation and lead innovation in future medical technologies.

The signing ceremony, held at SNUBH on Wednesday, was attended by Professor Lee Hak-jong, Director of the Biomedical Research Institute at SNUBH, and Sasha Semienchuk, General Manager of Novo Nordisk Korea.

The partnership aims to promote advancements not only in Novo Nordisk's key areas of diabetes, obesity, hemophilia, and growth hormone disorders but also in emerging fields like digital health.

By ensuring high-quality clinical trials, the collaboration seeks to expand opportunities for Korean patients with chronic diseases to participate in global clinical trials. It will also facilitate the integration of advanced technologies into innovative drug development, positioning Korean researchers as central contributors to cutting-edge clinical research.

"This MOU reflects our shared commitment to broadening the scope of global clinical trials conducted in Korea and contributing to the development of innovative treatments for chronic diseases,” Professor Lee said.

Novo Nordisk Korea GM Semienchuk also said, "This partnership with SNUBH marks a significant step in exploring not only traditional clinical research but also advancements in digital health and other future medical technologies.”

Together with SNUBH, the company aims to build on Novo Nordisk's century-long legacy of research into chronic and rare diseases by spearheading innovation in healthcare, he added.